EE542 Assessment of the Cost-Effectiveness of Risk Factor Guided Prophylaxis with Palivizumab for the Prevention of Severe Respiratory Syncytial Virus Infection in Colombian Infants Born at 32–35 Weeks’ Gestational Age
Title:
EE542 Assessment of the Cost-Effectiveness of Risk Factor Guided Prophylaxis with Palivizumab for the Prevention of Severe Respiratory Syncytial Virus Infection in Colombian Infants Born at 32–35 Weeks’ Gestational Age
Author:
Rodriguez-Martinez, C.E. Ordonez, J. Carbonell-Estrany, X. Fullarton, J. Keary, I. Rodgers-Gray, B. D'Apremont, I. Espinosa, S.M. Ribeiro, P.A. Stein, R. Vain, N. Tarride, J.E. Paes, B.